forzinity label: Public Product Information Summary
Disclaimer: All content on this site is based on public academic research and clinical data for educational and informational reference only. It is not medical advice. No treatment or health-related decisions should be made based solely on website content. This site does not sell pharmaceuticals or endorse any medical treatment.
What the label is
The prescribing information for forzinity — the FDA-approved label — is the single most checkable public document in this entire topic space: the reference form of every claim about the product's identity, dosing data, storage, safety frequencies and monitoring language. This page is a structured summary of it for research readers; the label itself is public at the FDA's document site, and our official resources page links the entry points.
A structured label summary earns its keep by preventing drift. Most “forzinity label” search results paraphrase loosely enough to change meanings — regimen figures detached from populations, storage conditions generalized, monitoring language converted into advice. Every figure below is presented with the section it comes from, so the summary stays anchored to its source document.
The label's core product data
Identity and strength: elamipretide, supplied as a 280 mg/3.5 mL (80 mg/mL) multi-dose vial for subcutaneous administration. The dosing-and-administration section documents the 40 mg daily labeled regimen and the renal-impairment figure (20 mg daily); the pharmacokinetic section reports the ≈4-hour terminal half-life. Full parameter table below; the regimen data page carries the administration-side detail (forzinity dosage data).
Storage and handling: 2–8°C refrigeration with an 8-day in-use window after first puncture — parameters that follow from the multi-dose vial design and that the label states explicitly. The safety sections (adverse-reaction frequencies, laboratory monitoring including the eosinophilia language) are summarized with their sources on the safety overview and the eosinophilia page.
The indication section — the boundary of the product's documented use
The label's indication section is the approved use: Barth syndrome, muscle-strength improvement, within the documented weight threshold — granted through the accelerated pathway on the TAZPOWER evidence documented on the fda page. Everything else the molecule has been associated with (heart failure, AMD, myopathy research) lives outside the label, as investigational history documented in the trials pillar.
That boundary is why label literacy matters for searchers: claims that cross it — about conditions, populations or effects not in the label — are by definition outside the product's documented use, whatever their scientific pedigree elsewhere in the molecule's literature. The label is the product's claims boundary; the literature is the molecule's research frontier; and confusing the two is the signature error of this topic space.
Reading labels well: a mini-method
Labels are structured documents with predictable sections, and the structure is the reading aid: identity/strength, indications, dosage and administration, contraindications and warnings, adverse reactions, pharmacology, storage. Finding the right section is faster and more reliable than any search-snippet paraphrase — and comparing sections across documents (label vs trial publication vs catalog COA) is the source discipline this site teaches throughout.
The data-usage steps below adapt the site's three-step discipline to label reading specifically: section-anchored extraction, population-normalized comparison, and source-grading that puts the label at the top of the domestic tier. Where this summary and the label itself ever differ, the label wins — unconditionally.
How to use the data on this page
Step 1 — extract the parameters. Extract each figure with its label section: strength (280 mg/3.5 mL), regimen (40 mg daily), renal figure (20 mg daily), storage (2–8°C), in-use window (8 days), half-life (≈4 h), weight threshold (30 kg). Section anchoring is what keeps paraphrase drift out of citations.
Step 2 — normalize before comparing. Normalize label figures against other document types before combining them: label frequencies describe approved populations; trial publications describe study populations; catalog COAs describe chemical lots. The table below carries the source column for exactly this reason.
Step 3 — grade the source. Grade the source: the prescribing information is the top domestic tier for product claims and overrides every summary — including this one — on any discrepancy.
Parameter comparison
forzinity label parameters, organized by the label sections they come from.
| Label section | Documented parameters | Notes |
|---|---|---|
| Identity / strength | elamipretide; 280 mg/3.5 mL (80 mg/mL) multi-dose vial | Subcutaneous product |
| Indication | Barth syndrome — muscle strength improvement; weight ≥30 kg | Accelerated approval, 2025 |
| Dosage & administration data | 40 mg daily; renal impairment 20 mg daily | Data documentation, not guidance |
| Pharmacokinetics | Terminal half-life ≈4 hours | Consistent with ss-31 literature |
| Storage | 2–8°C; 8-day in-use window after first puncture | Multi-dose vial design |
| Adverse reactions | Erythema 100%, pain 75%, pruritus 67% | See safety overview |
| Laboratory monitoring | Includes eosinophilia monitoring language | See eosinophilia page |
| Reference status | The label overrides all summaries on discrepancies | Editorial policy |
Table: forzinity label parameters, organized by the label sections they come from. — compiled from public regulatory and academic sources; verify against the original documents before use.
Frequently asked questions
What does the forzinity label say?
In brief: elamipretide as a 280 mg/3.5 mL (80 mg/mL) multi-dose vial for subcutaneous administration; the Barth syndrome indication under accelerated approval; 40 mg daily labeled regimen data with a 20 mg renal-impairment figure; storage at 2–8°C with an 8-day in-use window; and safety data dominated by injection-site frequencies. This page summarizes the public label for research reference; the label itself is the authoritative document.
References
- FDA forzinity (elamipretide) prescribing information — all sections, accessdata.fda.gov.